Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.

[1]  A. Shaw,et al.  LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study , 2020 .

[2]  Jie Yang,et al.  Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Ahn,et al.  Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L. , 2020 .

[4]  K. Venkatakrishnan,et al.  Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced Non-Small Cell Lung Cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  S. Digumarthy,et al.  Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Young Hak Kim,et al.  Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. , 2019, Lung cancer.

[7]  Edward S. Kim,et al.  Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  Edward S. Kim,et al.  Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial , 2019, Annals of Oncology.

[9]  N. Rizvi,et al.  Management strategies for early onset pulmonary events associated with brigatinib. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  A. Valipour,et al.  Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution. , 2019, Anti-cancer drugs.

[11]  N. Pavlakis,et al.  Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Edward S. Kim,et al.  Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)−positive, advanced non–small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib. , 2019, Journal of Clinical Oncology.

[13]  R. Doebele,et al.  Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC). , 2019, Journal of Clinical Oncology.

[14]  A. Shaw,et al.  ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Shaw,et al.  Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. , 2018, The Lancet. Oncology.

[16]  C. Gridelli,et al.  Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[17]  Young Hak Kim,et al.  Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9 , 2018, Cancer science.

[18]  Xin Zhang,et al.  Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis , 2018, Frontiers in Oncology.

[19]  Kenneth L. Jones,et al.  Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer , 2018, Clinical Cancer Research.

[20]  Robert Jones,et al.  The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) , 2018, Molecular Cancer.

[21]  Young Hak Kim,et al.  Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial , 2017, The Lancet.

[22]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[23]  Edward S. Kim,et al.  Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M Kieser,et al.  Point estimation and p‐values in phase II adaptive two‐stage designs with a binary endpoint , 2017, Statistics in medicine.

[25]  Serafino Pantano,et al.  First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study , 2017, The Lancet.

[26]  T. Clackson,et al.  The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models , 2016, Clinical Cancer Research.

[27]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .

[28]  T. Clackson,et al.  Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. , 2016, Journal of Medicinal Chemistry.

[29]  Jean Mosser,et al.  Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.

[30]  T. Clackson,et al.  1292PALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  M. Ladanyi,et al.  ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[32]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[33]  S. Digumarthy,et al.  Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study. , 2018 .

[34]  G. Scagliotti,et al.  Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.